Please login to the form below

Not currently logged in
Email:
Password:

Zelluna Immunotherapy appoints chief technology officer

Arjan Roozen will consolidate the biotech’s manufacturing strategy

Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.

Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.

Roozen’s career history has also seen him serve in numerous positions for Pharmacell, which was recently acquired by Lonza.

Miguel Forte, chief executive officer of Zelluna, said: “Zelluna appointed Arjan specifically for his wide-ranging knowledge in key areas of cell therapy product manufacturing.

“His experience, acquired on both side’s of the Atlantic will provide invaluable for Zelluna in its immediate focus of delivering clinical proof of concept of its TCRs in adoptive cell therapy for solid cancers.

“He will play a big part in the execution of Zelluna’s manufacturing strategy for clinical trials and commercialisation.”

20th April 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....